CLINICAL TRIALS PROFILE FOR BELINOSTAT
✉ Email this page to a colleague
All Clinical Trials for BELINOSTAT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00274651 ↗ | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | Terminated | Onxeo | Phase 2 | 2006-01-01 | Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle. |
| NCT00301756 ↗ | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | Completed | National Cancer Institute (NCI) | Phase 2 | 2006-09-01 | This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant potential tumors. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT00303953 ↗ | PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2006-01-01 | This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. |
| NCT00321594 ↗ | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2006-05-01 | This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth |
| NCT00334789 ↗ | Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | Completed | National Cancer Institute (NCI) | Phase 1 | 2006-06-12 | This phase I trial is studying the side effects and best dose of belinostat when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors. Belinostat may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Isotretinoin may cause solid tumor cells to look more like normal cells, and to grow and spread more slowly. Giving belinostat together with isotretinoin may be an effective treatment for metastatic or unresectable solid tumors. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BELINOSTAT
Condition Name
Clinical Trial Locations for BELINOSTAT
Trials by Country
Clinical Trial Progress for BELINOSTAT
Clinical Trial Phase
Clinical Trial Sponsors for BELINOSTAT
Sponsor Name
